Ultra-LEAF™ Purified anti-human GM-CSF Antibody

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

E. coli -expressed, recombinant human GM-CSF

Formulation

0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.

Endotoxin Level

Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.

Preparation

The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Concentration

The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.

Application

ELISA Capture - Quality tested
ELISPOT Capture, Neut, IP, WB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 0.25 - 1.0µg/mL is recommended. To obtain a linear standard curve, serial dilutions of GM-CSF recombinant protein ranging from 500 to 4 pg/mL are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA or ELISPOT Capture^1-6: The Purified BVD2-23B6 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD2-21C11 antibody (Cat. No. 502304) as the detecting antibody. The Ultra-LEAF™ Purified antibody is suggested for ELISPOT capture.
Neutralization^1-4: The Ultra-LEAF™ Purified antibody (Endotoxin <0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human GM-CSF bioactivity (Cat. Nos. 502205 - 502210).
Additional reported applications (for the relevant formats) include: immunoprecipitation³ and Western blotting.
Note: For testing human GM-CSF in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. Nos. 432001 and 432004) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)

1. Bacchetta R, et al. 1990. J. Immunol. 144:902.
2. Kita H, et al. 1991. J. Exp. Med. 174:745.
3. Abrams J, et al. 1992. Immunol. Rev. 127:5.
4. Abrams J, et al. 1994. Eosinophils in Allergy and Inflammation. Marcel Dekker New York. p.133.
5. Mahanty S, et al. 1992. J. Immunol. 148:3567.
6. Klinman D, et al. 1994. Curr. Prot. Immunol.. John Wiley and Sons New York. Unit 6.19.

RRID

AB_2832790 (BioLegend Cat. No. 502205)
AB_2832790 (BioLegend Cat. No. 502206)
AB_2832790 (BioLegend Cat. No. 502207)
AB_2832790 (BioLegend Cat. No. 502208)
AB_2832790 (BioLegend Cat. No. 502209)
AB_2832790 (BioLegend Cat. No. 502210)

Antigen Details

Structure

Cytokine; 22 kD (Mammalian)

Bioactivity

Growth/development granulocyte/macrophage progenitors; differentiates myeloblasts/monoblasts; synergizes with Epo proliferation of erythroid/megakaryocytic progenitors

Cell Sources

T cells, macrophages, fibroblasts, endothelial cells, mast cells

Cell Targets

Granulocyte/macrophage/erythroid/megakaryocytic progenitors, myeloblasts, monoblasts

Receptors

Heterodimer GM-CSFR α subunit (CDw116); β-subunit (CDw131) which is also shared the IL-3 and IL-5 receptor α chains

Biology Area

Cell Biology, Stem Cells

Molecular Family

Cytokines/Chemokines, Growth Factors

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Demetri G, et al. 1991. Blood 78:2791.
3. Fan D, et al. 1991. In vivo 5:571.
4. Negrin R, et al. 1992. Adv. Pharmacol. 23:263.

Regulation

Synergistic with IL-1, IL-3, G-CSF; E21R competitive antagonist for receptor binding; stored in ECM with heparan sulfate proteoglycans

Gene ID

1437 View all products for this Gene ID

Specificity (DOES NOT SHOW ON TDS):

GM-CSF

Specificity Alt (DOES NOT SHOW ON TDS):

GM-CSF

App Abbreviation (DOES NOT SHOW ON TDS):

ELISA Capture,ELISPOT Capture,IP,Neut,WB

UniProt

View information about GM-CSF on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Active Protocols: Sandwich ELISA - Video
• Sandwich ELISA Protocol

Related Pages & Pathways

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Other Formats

Certificate of Analysis